Specifications
- Purity
- ≥97% (NMR)
- Appearance
- Gray, purple or blue powder
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO, DMF (20 mg/ml), water (slightly)
Documentation
- Safety Data Sheet (SDS)
- CDX M0161 SDS.pdf
Available from stock
Mitomycin C
- SKU
- M0161
Categories:
- Synonyms
- Ametycine , Mutamycin , MMC , Mitocin-C , MitoExtra , Mitonco , Mitoplus , NSC 26980
- 50-07-7
- CAS-Number
- C15H18N4O5
- Molecular Formula
- 334.33
- Molecular Weight
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
- Shipping
- AMBIENT
- Short Term Storage
- +4°C
- Long Term Storage
- +4°C
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at +4°C.
- Hazard statements
- H302-H351
- Precautionary statements
- P280-P301 + P312 + P330
- GHS Symbol
- GHS07+GHS08
- Signal word
- Warning
- Transportation
- Not dangerous goods
- Description
- Mitomycin C (MMC) is an antitumor antibiotic. This product is an alkylating agent that specifically targets the guanine nucleoside sequence 5?-CpG-3?. It inhibits DNA synthesis by covalently reacting with DNA, forming crosslinks between complementary strands of DNA. This interaction prevents separation of complementary DNA strands, inhibiting DNA replication. Mitomycin C causes the cross-linking of double-stranded DNA, which results in mutagenesis, inhibition of DNA synthesis, initiation of DNA repair events, and activation of apoptosis. In tissue culture, this compound decreases cell viability and suppresses mitosis, and causes disorganization of nucleus and the production of giant cells. Mitomycin C has strong antitumor activity, especially against Ehrlich ascites tumor cells, and strong bactericidal action against gram-positive and gram-negative bacteria. Mitomycin C from Streptomyces caespitosus has been used for the treatment of feeder layers such as, PMEF (primary mouse embryonic fibroblasts) and CD1 mouse embryonic fibroblasts (MEFs) for the culture of hESCs (human embryonic stem cells). It has also been used for the treatment of BLC (basal-like cancer) cell line.
- Smiles
- CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N
- InChi Key
- NWIBSHFKIJFRCO-BNVMVXHRSA-N
- References
- (1) F.S. Philips, et al., Cancer Res. 20, 1354 (1960) , (2) V.N. Iyer & W. Szybalski, PNAS 50, 355 (1963) , (3) M. Tomasz, et al., Science 235, 1204 (1987) , (4) M. Tomasz, et al., Biochemistry 27, 3182 (1988) , (5) M. Tomasz, Chem. Biol. 2, 575 (1995) , (6) G.R. Merlo, et al., J. Cell Biol. 128, 1185 (1995) , (7) Y. Mao, et al., Chem. Biol. 6, 251 (1999) , (8) Y. Kato, et al., In Vivo 19, 301 (2005) , (9) V. Bryja, et al., Nat. Protoc. 1, 2082 (2006) , (10) C.Y. Park, et al., Nat. Protoc. 11, 2154 (2016)
Mitomycin C (MMC) is an antitumor antibiotic. This product is an alkylating agent that specifically targets the guanine nucleoside sequence 5?-CpG-3?. It inhibits DNA synthesis by covalently reacting with DNA, forming crosslinks between complementary strands of DNA. This interaction prevents separation of complementary DNA strands, inhibiting DNA replication. Mitomycin C causes the cross-linking of double-stranded DNA, which results in mutagenesis, inhibition of DNA synthesis, initiation of DNA repair events, and activation of apoptosis. In tissue culture, this compound decreases cell viability and suppresses mitosis, and causes disorganization of nucleus and the production of giant cells. Mitomycin C has strong antitumor activity, especially against Ehrlich ascites tumor cells, and strong bactericidal action against gram-positive and gram-negative bacteria. Mitomycin C from Streptomyces caespitosus has been used for the treatment of feeder layers such as, PMEF (primary mouse embryonic fibroblasts) and CD1 mouse embryonic fibroblasts (MEFs) for the culture of hESCs (human embryonic stem cells). It has also been used for the treatment of BLC (basal-like cancer) cell line.
Additional information
| Synonyms | Ametycine, Mutamycin, MMC, Mitocin-C, MitoExtra, Mitonco, Mitoplus, NSC 26980 |
|---|---|
| Purity | ≥97% (NMR) |
| Appearance | Gray, purple or blue powder |
| CAS-Number | 50-07-7 |
| Molecular Formula | C15H18N4O5 |
| Molecular Weight | 334.33 |
| Identity | 1H-NMR |
| Solvents | DMSO, DMF (20 mg/ml), water (slightly) |
| Smiles | CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N |
| InChi Key | NWIBSHFKIJFRCO-BNVMVXHRSA-N |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Hazard statements | H302-H351 |
| Precautionary statements | P280-P301 + P312 + P330 |
| GHS Symbol | GHS07+GHS08 |
| Signal word | Warning |
| Transportation | Not dangerous goods |
| References | (1) F.S. Philips, et al., Cancer Res. 20, 1354 (1960), (2) V.N. Iyer & W. Szybalski, PNAS 50, 355 (1963), (3) M. Tomasz, et al., Science 235, 1204 (1987), (4) M. Tomasz, et al., Biochemistry 27, 3182 (1988), (5) M. Tomasz, Chem. Biol. 2, 575 (1995), (6) G.R. Merlo, et al., J. Cell Biol. 128, 1185 (1995), (7) Y. Mao, et al., Chem. Biol. 6, 251 (1999), (8) Y. Kato, et al., In Vivo 19, 301 (2005), (9) V. Bryja, et al., Nat. Protoc. 1, 2082 (2006), (10) C.Y. Park, et al., Nat. Protoc. 11, 2154 (2016) |
| Quantity | 5 mg, 10 mg, 25 mg, Bulk |
